← Back to TCM Global · All articles
2026-10-23
In August 2026, Xin'an Bio (欣苷生物) — the skincare brand incubated by Giant Biogene with beauty e-commerce operator Youke — announced the closure of its original stores, with both parents confirming the partnership restructuring.
For an ingredient with registered production, heritage story and corporate backing, the closure is instructive rather than damning. Here's what it teaches.
Xin'an had a genuinely differentiated active (rare saponins) and credible science. But consumer brands win on narrative resonance, channel rhythm and community — crafts distinct from chemistry. The closure reflects a craft mismatch, not a product failure.
The Giant Biogene + Youke pairing combined biotech with e-commerce operations — logical on paper. But when growth stalled, the partners' incentives and capabilities diverged. JV structures for new categories need pre-agreed pivots, or they lock both sides into failing strategies.
Rare saponins require consumer education — nobody wakes up asking for Rk3. Building that understanding takes content, community and time. A launch-heavy, education-light approach burns cash before the market understands the value.
The closure preceded (by weeks) both the CK registration and the new brand launch. Reading the sequence: the vehicle closed, the program continued. Killing a underperforming brand quickly preserved resources for a better-built successor — 1'me Yiwuo, launched into mass channels with a focused single-product strategy.
Through every brand cycle, the compounding assets were the ingredient registration, production scale and technical data. Companies should structure themselves so brands can fail without the technology failing.
The Xin'an story is not a eulogy — it is tuition paid. The ginsenoside program now entering mass retail is stronger for the closed brand. In ingredient biotech, brands are experiments; registered actives are theorems.
Explore more Eastern wellness wisdom at TCM Global.